Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations.
AuthorsBrown, Michael D
Gilmore, Paul E
Hart, Claire A
Samuel, Joanne D
Ramani, Vijay A C
George, Nicholas J
Clarke, Noel W
AffiliationProMPT Genito-Urinary Cancer Research Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractBACKGROUND: The prostate epithelial stem cell has been proposed as the primary origin of neoplastic change in prostate cancer. However, the isolation and characterization of unexpanded prostate epithelial stem cells have proven problematic. METHODS: A prostate epithelial side population (SP) has been isolated utilizing a modified Hoechst 33342 dye efflux assay from both benign and malignant prostate tissue. CD45(-ve), integrin alpha2(+ve) Hoechst 33342 SP and NSP cells were isolated by FACS, immunophenotyped and functionally characterized in 3D culture. RESULTS: FACS analysis revealed a verapamil sensitive SP accounting for 0.93 +/- 0.12% and 0.57 +/- 0.11% of the total epithelial population from both benign and malignant prostates. The benign SP phenotype revealed a heterogeneous cell population consisting predominantly of small basal cells containing minimal cytoplasm. Conversely, the malignant SP was of undetermined acinar origin and with a complete loss of expression of the CDK2 inhibitor p21(WAF1/Cip1). In vitro androgen-enhanced 3D culture of the benign and malignant SP cells led to the production of spheroids which had acinus like morphology and expressed primitive and basal cell markers. Incorporation of the CD133 marker isolated a further SP sub-fraction accounting for 0.037 +/- 0.01% of epithelial cells. CONCLUSIONS: Our observations are consistent with the Hoechst 33342 dye efflux assay isolating a stem cell enriched population which can be further sub-fractionated by CD133 selection. Moreover, the loss of the CDK inhibitor in malignancy is consistent with the hypothesis that neoplastic change originates in the stem cell compartment.
CitationCharacterization of benign and malignant prostate epithelial Hoechst 33342 side populations. 2007, 67 (13):1384-96 Prostate
- Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer.
- Authors: Pellacani D, Packer RJ, Frame FM, Oldridge EE, Berry PA, Labarthe MC, Stower MJ, Simms MS, Collins AT, Maitland NJ
- Issue date: 2011 Jul 29
- Novel method for the isolation and characterisation of the putative prostatic stem cell.
- Authors: Bhatt RI, Brown MD, Hart CA, Gilmore P, Ramani VA, George NJ, Clarke NW
- Issue date: 2003 Aug
- Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem-like phenotype.
- Authors: Srivastava VK, Nalbantoglu J
- Issue date: 2008 Oct
- Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens.
- Authors: Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S, Rhim JS
- Issue date: 2007 Apr 1
- Expression profiling of CD133+ and CD133- epithelial cells from human prostate.
- Authors: Shepherd CJ, Rizzo S, Ledaki I, Davies M, Brewer D, Attard G, de Bono J, Hudson DL
- Issue date: 2008 Jun 15